Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aeglea Biothera
(NQ:
AGLE
)
7.980
USD
-0.230 (-2.80%)
Official Closing Price
Updated: 4:21 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Aeglea Biothera
< Previous
1
2
3
Next >
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today...
From
PR Newswire
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
December 17, 2020
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden...
From
PR Newswire
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
December 01, 2020
Company eligible to receive Priority Review Voucher upon FDA approval of ACN00177
From
PR Newswire
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
November 24, 2020
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden...
From
PR Newswire
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
November 17, 2020
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden...
From
PR Newswire
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 05, 2020
Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177
From
PR Newswire
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
October 26, 2020
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden...
From
PR Newswire
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
October 05, 2020
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden...
From
PR Newswire
Aeglea BioTherapeutics to Participate in September Investment Conferences
September 02, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
August 18, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
August 10, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020
May 28, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 26, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 19, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
May 07, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 30, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
April 28, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Proposed Public Offering
April 27, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
April 08, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
February 24, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
January 13, 2020
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020
From
GlobeNewswire News Releases
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
November 26, 2019
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
November 06, 2019
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
November 04, 2019
From
GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference
September 05, 2019
Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
September 03, 2019
From
GlobeNewswire News Releases
Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
August 29, 2019
Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
August 06, 2019
From
GlobeNewswire News Releases
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
July 24, 2019
Designation Follows Recently Reported ARG1-D Phase 1/2 Data Demonstrating Clinical Response in Patients Treated with Pegzilarginase
From
GlobeNewswire News Releases
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.